{"References": [{"title": "Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy", "authors": "Palmer, Adam C., Sorger, Peter K.", "journal": "Cell", "year": "2017", "volumes": "171", "first page": "1678", "last page": "1691.e13", "DOI": "10.1016/j.cell.2017.11.009"}, {"title": "Collateral sensitivity of drug-resistant ABCB5-positive melanoma cells to the survivin inhibitor YM155", "authors": "Frank, Natasha Y., Schatton, Tobias, Kim, Soo, Zhan, Qian, Wilson, Brian J., Ma, Jie, Saab, Karim R., Osherov, Veronika, Widlund, Hans R., Gasser, Martin, Waaga-Gasser, Ana Maria, Kupper, Thomas S., Murphy, George F., Frank, Markus H.", "journal": "Molecular Cancer Therapeutics", "year": "2011", "volumes": "10", "first page": "2924", "last page": "2933", "DOI": "10.1158/1535-7163.MCT-11-0338"}, {"title": "Synergistic effect of PD-1 blockade and BRAF inhibition in melanoma", "authors": "Ribas, Antoni, Hodi, F. Stephen, Callahan, Margaret, Konto, Cyndi, Wolchok, Jedd", "journal": "Nature Medicine", "year": "2013", "volumes": "19", "first page": "935", "last page": "936", "DOI": "10.1038/nm.3218"}, {"title": "Combination therapy with PD-1 or PD-L1 inhibitors for cancer", "authors": "Mahoney, Kathleen M., Freeman, Gordon J., McDermott, David F.", "journal": "Nature Reviews Clinical Oncology", "year": "2015", "volumes": "12", "first page": "563", "last page": "582", "DOI": "10.1038/nrclinonc.2015.140"}, {"title": "Collateral sensitivity as a strategy against cancer multidrug resistance", "authors": "Pluchino, Kristen M., Hall, Matthew D., Goldsborough, Andrew S., Callaghan, Richard, Gottesman, Michael M.", "journal": "Drug Resistance Updates", "year": "2012", "volumes": "15", "first page": "98", "last page": "105", "DOI": "10.1016/j.drup.2012.03.002"}, {"title": "The concept of synthetic lethality in the context of anticancer therapy", "authors": "Kaelin, William G.", "journal": "Nature Reviews Cancer", "year": "2005", "volumes": "5", "first page": "689", "last page": "698", "DOI": "10.1038/nrc1691"}, {"title": "Combination therapy in combating cancer", "authors": "Chou, Ting-Chao", "journal": "Pharmacological Reviews", "year": "2006", "volumes": "58", "first page": "621", "last page": "681", "DOI": "10.1124/pr.58.3.10"}, {"title": "PD-1 blockade induces responses by inhibiting adaptive immune resistance", "authors": "Tumeh, Paul C., Harview, Christina L., Yearley, Jennifer H., Shintaku, I. Peter, Taylor, Emma J.M., Robert, Lidia, Chmielowski, Bartosz, Spasic, Marko, Henry, Gina, Ciobanu, Vlad, West, Alisha N., Carmona, Manuel, Kivork, Christine, Seja, Elizabeth, Cherry, Grace, Gutierrez, Antonio J., Grogan, Tristan R., Mateus, Christine, Tomasic, Gorana, Glaspy, John A., Emerson, Ryan O., Robins, Harlan, Pierce, Robert H., Elashoff, David A., Robert, Caroline, Ribas, Antoni", "journal": "Nature", "year": "2014", "volumes": "515", "first page": "568", "last page": "571", "DOI": "10.1038/nature13954"}, {"title": "Mechanisms of resistance to PD-1 and PD-L1 blockade", "authors": "Sharma, Padmanee, Hu-Lieskovan, Siwen, Wargo, Jennifer A., Ribas, Antoni", "journal": "Cancer Journal", "year": "2018", "volumes": "24", "first page": "47", "last page": "53", "DOI": "10.1097/PPO.0000000000000303"}, {"title": "The future of immune checkpoint therapy", "authors": "Pardoll, Drew M.", "journal": "Science", "year": "2012", "volumes": "355", "first page": "1160", "last page": "1165", "DOI": "10.1126/science.1223549"}]}